drugset / Trial / NCT05328154

MAGnesium Effect With ANtiosteoporotic Drugs

NCT05328154

Phase 2 Completed 45 enrolled University Hospital, Clermont-Ferrand
RandomizedParallel-groupOpen-labelTreatment

Summary

Randomized pilot clinical trial to demonstrate superiority of bisphosphonate-magnesium combination over bisphosphonates alone in postmenopausal osteoporosis in slowing bone remodeling as assessed by C-terminal telopeptide of bone collagen type 1 (CTX) dosage.

Timeline

Start
2022-06-28
Primary completion
2024-12-19
Completion
2024-12-19

Drugs

EvaluationDrugModalityDoseRoute
Comparator Magnesium carbonate Small molecule 200 mg Oral
Comparator Zoledronic acid Other / unclassified 5 mg Intravenous